Needham Reiterates Buy on Biogen, Maintains $323 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Ami Fadia has reiterated a 'Buy' rating on Biogen (NASDAQ:BIIB) and maintained a price target of $323.

July 31, 2023 | 8:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biogen's stock rating has been reiterated as 'Buy' by Needham analyst Ami Fadia, with a maintained price target of $323.
The reiteration of a 'Buy' rating by a reputable analyst like Ami Fadia from Needham is a positive signal for investors. The maintained price target of $323 indicates that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100